Matteo Lambertini, MD
Enriched profileDirector of Medical Oncology, Galliera Hospital (Genoa) · Ente Ospedaliero Ospedali Galliera
Matteo Lambertini is Director of Medical Oncology, Galliera Hospital (Genoa) at Ente Ospedaliero Ospedali Galliera. OpenAlex indexes 737 publications with 17,842 citations (h-index 67); ClinicalTrials.gov lists 5 registered studies with this person as an investigator.
Data verified 9 Nov 2026
Overview
Updated 10 Nov 2026
Matteo Lambertini is Director of Medical Oncology, Galliera Hospital (Genoa) at Ente Ospedaliero Ospedali Galliera. The public record shows 737 publications with 17,842 citations (h-index 67), centered on Breast Cancer Treatment Studies, BRCA gene mutations in cancer, Reproductive Biology and Fertility. It also documents an investigator role on 5 registered clinical trials.
- Most recent indexed publication: 2026 · European journal of clinical investigation
- Top research focus: Breast Cancer Treatment Studies
- 5 registered trials on ClinicalTrials.gov
Generated from the cited public record · current as of 10 Nov 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. 111 in PubMed. Counts exclude supporting files.
Citations across these publications.
H-index from these publications. i10-index 264.
Clinical & industry
trials, payments and federal fundingNot shown. No U.S. clinical registration on file.
Federally funded research awards.
This is a research profile, built on the published record. There's no U.S. clinical registration (NPI) on file, so facts that hang off one (clinical specialty, industry payments) aren't shown. We'd rather leave a gap than guess. Why? →
Contact
No public contact details on file. Research profiles have no U.S. clinical registration, so there's no federal registry record to draw an address or phone from. Why? →
Clinical trials
Updated 9 Nov 2026
Listed as an investigator on 5 registered studies on ClinicalTrials.gov. The most recent:
- Pregnancy Outcomes After Breast Cancer in Young Women With Germline Pathogenic Variants in Genes Other Than BRCA
Sponsor: Jules Bordet Institute
- Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemoimmunotherapy and a FASTing-like Approach in the Preoperative Setting: the BREAKFAST 2 Trial
Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Industry payments
Not shown. This person has no U.S. clinical registration (NPI) on file, so we can't reliably tie industry payments reported to CMS to them. We'd rather leave a gap than guess. Why? →
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 9 Nov 2026
140 congress contributions (2013–2026) across AACR, ASCO, ASH, ESHRE Annual Meeting, ESMO, ESTRO Congress, SABCS per OpenAlex. The most recent:
- Cumulative incidence and risk factors of trastuzumab deruxtecan–related interstitial lung disease in a multicenter real-world cohort.
ASCO Annual Meeting
ASCO2026Co-author - De-escalated chemotherapy and endocrine therapy outcomes in young women with stage I HR+/HER2+ breast cancer: An international real-world study.
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 9 Nov 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Fertility Treatment and Risk of Melanoma: A Certainty-Rated Systematic Review and Meta-Analysis of 3,733,499 Women.
European journal of clinical investigation
Meta-analysis2026 - World Health Organization classification of tumours of the breast 6th edition 2026.
Histopathology
Review2026 - The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a subanalysis of the APHINITY trial.
Journal of the National Cancer Institute
Clinical Trial2026 - Prognostic impact of phosphatase and tensin homolog status in recurrent IDH-wildtype glioblastoma receiving second-line therapy.
Neuro-oncology advances
Article2026 - Outcomes and treatment patterns in germline BRCA1/2 carriers from two matched cohort studies.
JNCI cancer spectrum
Article2026
Congress posts on X
Post links from an X account tied to this person through reviewed identity evidence.
Listed under ESMO 2026
Listed under ESMO 2026
Listed under ESMO 2026
These links cover selected congress pages. They do not establish attendance or a complete posting history. Post availability may change.
Online presence
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- X / Twitter
x.com/matteolambe
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 9 Nov 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
PhD
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youngsurvival.org ↗
Editorial & leadership roles
journal and society appointments- Board member
ISFP
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cor2ed.com ↗ - Member of the executive board
Breast International Group (BIG)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cor2ed.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cor2ed.com ↗
- Member
ASCO Annual Meeting Scientific Program Committee, Breast Cancer Local/Regional/Adjuvant Track
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cor2ed.com ↗ - JCO Consultant Editor
Journal of Clinical Oncology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cor2ed.com ↗ - Chair
ESO Certificate of Competence in Breast Cancer
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cor2ed.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Nicoletta Sacchi
Ente Ospedaliero Ospedali Galliera
Cesare Massone
Ente Ospedaliero Ospedali Galliera
Claudio Marcello Solaro
Ente Ospedaliero Ospedali Galliera
Arnoldo Piccardo
Ente Ospedaliero Ospedali Galliera
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Eric Winer, MD
Yale School of Medicine
Norman Wolmark, MD
University of Pittsburgh
Hope Rugo, MD
City of Hope